Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.93 Analyst target: $12.50 Upside: 1244.09%
FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology, specifically targeting degenerative diseases and spinal disorders. The company's robust intellectual property portfolio and commitment to clinical excellence position it favorably within the rapidly evolving cellular therapy market. By fostering strategic partnerships and enhancing research initiatives, FibroBiologics aims to transform patient care and improve clinical outcomes with its cutting-edge therapeutic solutions.
See the full interactive analysis & chart →Informational only — not investment advice.